Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 19, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of share transactions rather than a financial performance report.
Material Changes
On January 17, 2006, Abacus (GSK) Trustees Limited, acting as trustee for the GlaxoSmithKline Employee Trust ("the GSK Trust"), transferred 11,950 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991. The Company was advised of these transactions on January 18, 2006.
Outlook, Risks, and Management Commentary
The GSK Trust is a discretionary trust where all current and former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries. Three directors—Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop—hold an interest in the shares held within the GSK Trust in the same capacity as other employees. The filing notes no specific risks, guidance, or unusual items beyond this standard disclosure.
Investor Verification Points
- Verify the total number of shares transferred (11,950) and the specific plan involved (SmithKline Beecham Employee Share Option Plan 1991).
- Confirm the date of the transaction (January 17, 2006) versus the date of company notification (January 18, 2006).
- Review the status of the three directors mentioned (Dr J-P Garnier, Dr T Yamada, Mr J S Heslop) regarding their interest in the GSK Trust.